News + Resources

Keep up with the latest

Featured

This Scientist Is Building Custom Gene-Editing Tools

This Scientist Is Building Custom Gene-Editing Tools

Epigenetic editors are a gentler form of gene editing

February 24, 2025

The Economist

Epigenetic editors are a gentler form of gene editing

February 24, 2025

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

CRISPR 2.0, the Next Generation

June 21, 2024

Aspen Ideas: Health

CRISPR 2.0, the Next Generation

June 21, 2024

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

TEDxBerkeley

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

All Stories

Exciting new CRISPR-CasX variant could be ‘Swiss army knife’ for genetics

February 5, 2019

Silicon Republic

Exciting new CRISPR-CasX variant could be ‘Swiss army knife’ for genetics

February 5, 2019

Silicon Republic

CRISPRMED25 Virtual Event Roundup

April 8, 2025

CRISPR Medicine News

From Tools to Trials: Editing Therapy Companies Pivot to Development

March 20, 2025

Genetic Engineering & Biotechnology News

Epigenetic editors are a gentler form of gene editing

February 24, 2025

The Economist

CRISPR’s cardio catch-all drives a biotech’s broad potential

February 18, 2025

PharmaVoice

Towards an AI-Driven CRISPR Future

February 11, 2025

SynBioBeta

2025 predictions: Which trends are set to shape the biotech industry this year?

January 13, 2025

Labiotech

Scribe Therapeutics Highlights Latest Data on Lp(a)-Lowering Therapy and Novel AI Platform for Next-Generation CRISPR-Based Therapeutics at Two Premier Conferences

September 9, 2025

Scribe Therapeutics to Demonstrate Scientific and Corporate Leadership at Upcoming Conferences

August 25, 2025

Scribe Therapeutics Reports Positive Preclinical Data on its Novel CRISPR Technologies at the 2025 EAS Congress and ASGCT Annual Meeting

May 22, 2025

Scribe Therapeutics to Highlight In Vivo CRISPR-based Genome Editing Data for Duchenne Muscular Dystrophy at ASGCT 2025, in Addition to Joint Presentation with Prevail Therapeutics, a part of Lilly’s Gene Therapy Division

May 5, 2025

Scribe Achieves Milestone for In Vivo Program in Collaboration with Prevail Therapeutics, a part of Lilly’s Gene Therapy Division, and Announces ASGCT Joint Presentation on Self-Inactivating AAV Technology for Neurological and Neuromuscular Disorders

April 28, 2025

Scribe Therapeutics to Unveil Latest Preclinical Data on Proprietary CRISPR Epigenetic Silencing Technology for LDL-C Lowering at the 2025 EAS Congress

April 23, 2025

Publications and presentations

Scribe Corporate Deck 2025 Q1

February 3, 2025

CasX enzymes comprise a distinct family of RNA-guided genome editors

February 4, 2019

Nature

Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes

May 1, 2017

Nature Biotechnology

Targeted gene knock-in by homology-directed genome editing using Cas9 ribonucleoprotein and AAV donor delivery

March 2, 2017

Nucleic Acids Research

Profiling of engineering hotspots identifies an allosteric CRISPR-Cas9 switch

June 1, 2016

Nature Biotechnology

Multi-reporter selection for the design of active and more specific zinc-finger nucleases for genome editing

January 7, 2016

Nature Communications

Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery

December 15, 2014

eLife

Programmable RNA recognition and cleavage by CRISPR/Cas9

December 11, 2014

Nature

MicroRNA-mediated switching of chromatin-remodelling complexes in neural development

July 30, 2009

Nature